TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20444243

Group type: EXPERIMENTAL
Intervention: Probiotic containing live lactobacillus acidophilus plus bifidobacterium bifidum
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17976815

Group type: EXPERIMENTAL
Intervention: 12‐min educational video on stroke developed by the American Stroke Association
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 16209244

Group type: EXPERIMENTAL
Intervention: Music therapy (15 min duration)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (without music therapy)
Number of subjects: 36
Study: 12051484

Group type: EXPERIMENTAL
Intervention: Educational intervention prior to engaging in an anxiety-provoking task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutralization after writing the sentence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo intervention control group
Number of subjects: 0
Study: 10336918

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sequential use of tests
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Side effects with glyceryl trinitrate
Number of subjects: 65
Study: 7478710

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 61
Study: 2149280

Group type: EXPERIMENTAL
Intervention: Toremifene 200 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene 400 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene (various doses)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene (doses >= 40 mg/day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene (all doses tested)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene (doses >= 60 mg/day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Toremifene (N-desmethyl and 4-hydroxy metabolites)
Number of subjects: 4
Study: 7307428

Group type: EXPERIMENTAL
Intervention: Methadone (7.5, 15, or 30 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine (10 or 20 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31764191

Group type: EXPERIMENTAL
Intervention: Stratified analgesia group (187 patients)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Conventional group (174 patients)
Number of subjects: 361
Study: 27897034

Group type: EXPERIMENTAL
Intervention: Meditative music (30 minutes)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (quiet rest for 40 minutes)
Number of subjects: 72
Study: 24880619

Group type: EXPERIMENTAL
Intervention: Intraorbital injections of rituximab (RTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous glucocorticoids (GCs)
Number of subjects: 20
Study: 22737998

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (0.05 mL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 61
Study: 21098908

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) with cross-sectional area (CSA) measures
Number of subjects: 17
Study: 19836952

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (specific dosage and duration not mentioned)
Number of subjects: 979
Study: 16872374

Group type: COMPARATOR
Intervention: Bifidobacterium animalis ssp. lactis (BB‐12) and Lactobacillus paracasei ssp. paracasei (CRL‐431) supplementation (0, 10^8, 10^9, 10^10, 10^11 CFU day(‐1) for 3 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis (BB‐12) and Lactobacillus paracasei ssp. paracasei (CRL‐431) supplementation
Number of subjects: 71
Study: 12926979

Group type: EXPERIMENTAL
Intervention: BOTOX®
Number of subjects: 264

Group type: COMPARATOR
Intervention: Topical agents (aluminum chloride) and iontophoresis
Number of subjects: 264
Study: 10706303

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic technique
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular laparoscopic technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 12
Study: 9133133

Group type: EXPERIMENTAL
Intervention: Whole gut lavage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral polyethylene glycol solution (Fordtran)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prepacol
Number of subjects: 100
Study: 8363995

Group type: EXPERIMENTAL
Intervention: tropisetron (5 mg/day; n = 115)
Number of subjects: 231

Group type: COMPARATOR
Intervention: optimal standard therapy (n = 116)
Number of subjects: 231
Study: 2424249

Group type: EXPERIMENTAL
Intervention: 1% minoxidil in unguentum merck
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (unguentum merck alone)
Number of subjects: 50
Study: 29198901

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 444

Group type: COMPARATOR
Intervention: CT
Number of subjects: 444

Group type: COMPARATOR
Intervention: CT vs MRI
Number of subjects: 444
Study: 27721123

Group type: EXPERIMENTAL
Intervention: Therapist-guided ACT
Number of subjects: 152
Study: 25026866

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) for ground-glass nodules
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP) for ground-glass nodules
Number of subjects: 8
Study: 23290427

Group type: EXPERIMENTAL
Intervention: Web-based surveys via e-mail
Number of subjects: 92

Group type: COMPARATOR
Intervention: In-person or telephone follow-up surveys
Number of subjects: 92
Study: 20205490

Group type: EXPERIMENTAL
Intervention: Sitagliptin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin as initial combination therapy with metformin or pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin add-on therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin as add-on treatment to metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin as add-on treatment to pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study: 19119599

Group type: EXPERIMENTAL
Intervention: Expression of p53 protein in NPSC
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Expression of p63 protein in NPSC
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Correlation between p53 and p63 protein in NPSC
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Expression of p73 protein in NPSC
Number of subjects: 67
Study: 16606452

Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no repaglinide)
Number of subjects: 12
Study: 15130047

Group type: EXPERIMENTAL
Intervention: Extraction group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 11878736

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine and hyaluronidase 150 U ml(‐1) in a volume of 4 or 5 ml
Number of subjects: 40
Study: 9779169

Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (Unasyn and Aztreonam)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Perioperative antibiotics only (Unasyn)
Number of subjects: 228
Study: 8154635

Group type: EXPERIMENTAL
Intervention: RG 12525 200 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RG 12525 25 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3163364

Group type: EXPERIMENTAL
Intervention: Low fat (31% of total kcal)/low cholesterol (193 mg/d) (LFLC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low fat/usual cholesterol (504 mg/d) (LFUC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Usual fat (46% of total kcal)/low cholesterol (UFLC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Usual fat/usual cholesterol (UFUC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low fat intake
Number of subjects: 4

Group type: COMPARATOR
Intervention: Usual fat intake
Number of subjects: 4
Study: 31905383

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Tenofovir Alafenamide (TAF)-based regimen
Number of subjects: 743
Study: 30246150

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg thrice daily)
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2000 mg once daily)
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg four times daily)
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Any combination of metoclopramide, ceftriaxone, paracetamol
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3800
Study: 27176931

Group type: EXPERIMENTAL
Intervention: Surgery + Postoperative Radiotherapy (PORT) (median dose: 45 Grays)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 599
Study: 25615888

Group type: EXPERIMENTAL
Intervention: Closed-loop technology (real-time continuous glucose monitoring with overnight closed-loop)
Number of subjects: 24
Study: 23758464

Group type: EXPERIMENTAL
Intervention: Tooth Mousse Plus
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pronamel
Number of subjects: 70
Study: 20627269

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 107
Study: 18771643

Group type: EXPERIMENTAL
Intervention: SPL7013 Gel
Number of subjects: 36
Study: 16520686

Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg/day, median stable dose 300 mg/day)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Modafinil (previous randomized modafinil group)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo (previous placebo group)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Modafinil (for former modafinil responders and placebo nonresponders)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Modafinil (general outcome)
Number of subjects: 245
Study: 12934740

Group type: COMPARATOR
Intervention: Fondaparinux for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fondaparinux for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 0
Study: 11145438

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b during induction, maintenance and relapse (NMSG 4/90)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon as maintenance after high-dose chemotherapy with stem cell support (NMSG 5/94)
Number of subjects: 0
Study: 9181655

Group type: EXPERIMENTAL
Intervention: Tobramycin 160 mg i.v. once daily for 2 days + Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Number of subjects: 73
Study: 8476407

Group type: EXPERIMENTAL
Intervention: Worrisome thinking (General-Worry)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoughts during worry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Images during worry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect experienced during worry
Number of subjects: 0
Study: 3535021

Group type: EXPERIMENTAL
Intervention: CBS coated tablets
Number of subjects: 189

Group type: COMPARATOR
Intervention: CBS chewing tablets
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: CBS coated tablets and CBS chewing tablets
Number of subjects: 189
Study: 30285814

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard disease information only (Control)
Number of subjects: 135
Study: 27733181

Group type: EXPERIMENTAL
Intervention: Innovative psychological therapy for depression (REFRAMED)
Number of subjects: 20
Study: 24553693

Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (quartile 4 vs. quartile 1)
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Insoluble fiber intake
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Legume fiber intake
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Soluble fiber intake
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Cereal fiber intake
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Vegetable fiber intake
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Fruit fiber intake
Number of subjects: 3313
Study: 22889722

Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs)
Number of subjects: 2346

Group type: EXPERIMENTAL
Intervention: Antidepressants (TCAs)
Number of subjects: 2346

Group type: EXPERIMENTAL
Intervention: Antidepressants (Miscellaneous)
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2346
Study: 20584776

Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) during exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise-induced CFI reserve
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coronary collateral conductance during exercise
Number of subjects: 30
Study: 18672988

Group type: EXPERIMENTAL
Intervention: Chlorine dioxide mouthrinse
Number of subjects: 77

Group type: COMPARATOR
Intervention: Chlorhexidine (0.20%) mouthrinse
Number of subjects: 77
Study: 15815935

Group type: EXPERIMENTAL
Intervention: High volume/low intensity exercise training for 6 months
Number of subjects: 6
Study: 14508313

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 10097932

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) at an initial dosage of 9.3 mg.kg‐1.day‐1 tapered to 7.0 mg.kg‐1.day‐1 for 12.5 +/- 4.0 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 14.4 +/- 3.8 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8732610

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine (group 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline (group 2)
Number of subjects: 22
Study: 1768544

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Number of subjects: 38

Group type: COMPARATOR
Intervention: Magnesium sulphate 40 mg kg‐1 and Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Number of subjects: 38
Study: 6763455

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isopaque Coronar
Number of subjects: 16
Study: 31977278

Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 120
Study: 31738342

Group type: EXPERIMENTAL
Intervention: Improved Water, Sanitation and Hygiene (WASH)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine (RVV)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Enteropathogen infections
Number of subjects: 224
Study: 28317676

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5% ophthalmic solution for 1 week postoperative
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5% ophthalmic solution for 1 month postoperative
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison between 1-week and 1-month postoperative groups
Number of subjects: 104
Study: 25820605

Group type: EXPERIMENTAL
Intervention: Internet website access (Intervention Group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Printed versions (Control Group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High interactions (HI)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: No interactions (NI)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 74
Study: 24634627

Group type: EXPERIMENTAL
Intervention: Bilateral BoNT‐A injections (25 U per muscle) into the masseter muscles only (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilateral BoNT‐A injections into both the masseter and temporalis muscles (group B)
Number of subjects: 20
Study: 22865871

Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone (0.5 mg/kg) for 3 days
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: High-dose oral prednisolone (2 mg/kg) for 3 days
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 19121875

Group type: EXPERIMENTAL
Intervention: Online instructional videos for teaching clinical nursing skills
Number of subjects: 0
Study: 17442556

Group type: EXPERIMENTAL
Intervention: BacoMind (300 mg for first 15 days, 450 mg for next 15 days)
Number of subjects: 23
Study: 15280341

Group type: EXPERIMENTAL
Intervention: Decision board (decision aid)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 201
Study: 11925573

Group type: EXPERIMENTAL
Intervention: PLUS Nursing Intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard Home Care
Number of subjects: 25
Study: 11193245

Group type: EXPERIMENTAL
Intervention: 1 mg E2V + 2.5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg E2V + 5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E2V + 2.5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E2V + 5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg E2V increased to 2 mg after 6 months + 2.5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg E2V increased to 2 mg after 6 months + 5 mg MPA
Number of subjects: 419

Group type: COMPARATOR
Intervention: 2.5 mg MPA
Number of subjects: 419

Group type: COMPARATOR
Intervention: 5 mg MPA
Number of subjects: 419
Study: 8704381

Group type: EXPERIMENTAL
Intervention: Handwashing education program including classroom presentations and follow-up activities
Number of subjects: 0
Study: 1592778

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.1 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6703506

Group type: EXPERIMENTAL
Intervention: Magnesium intravenously
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dextrose (placebo)
Number of subjects: 33
Study: 31315728

Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation (twice a day, 30 minutes each time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 60
Study: 29863741

Group type: EXPERIMENTAL
Intervention: Student-designed simulation project (SDSP) and Good Catch and Error Reporting (GCER) program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 49
Study: 26110230

Group type: EXPERIMENTAL
Intervention: Treadmill Training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Strength Training
Number of subjects: 28
Study: 24389523

Group type: EXPERIMENTAL
Intervention: Aerobic training (AER)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Aerobic + Resistance training (AER + RES)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Resistance training (RES)
Number of subjects: 262
Study: 22762857

Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacy dispensing data utilized)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group (standard admission process without community pharmacy data)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 487
Study: 20631558

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2949
Study: 18703813

Group type: EXPERIMENTAL
Intervention: Persistent hyperglycemia
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Delayed hyperglycemia at 24 hours
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Hyperglycemia at baseline only
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Dynamic patterns of hyperglycemia in patients with diabetes
Number of subjects: 748
Study: 15936036

Group type: EXPERIMENTAL
Intervention: Mannitol 20%, 100 ml every 4 h for 5 days, tapered in the next 2 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 128
Study: 12796019

Group type: EXPERIMENTAL
Intervention: FAC (doxorubicin 500 mg/m², cyclophosphamide 50 mg/m², fluorouracil 500 mg/m²) every 3 weeks for six cycles
Number of subjects: 985

Group type: COMPARATOR
Intervention: CMF (methotrexate 600 mg/m², cyclophosphamide 60 mg/m², fluorouracil 600 mg/m²) every 3 weeks for six cycles
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 985

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 985
Study: 10232210

Group type: EXPERIMENTAL
Intervention: Structured preoperative teaching program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video teaching
Number of subjects: 0
Study: 8915788

Group type: EXPERIMENTAL
Intervention: Blinded readings of X-rays
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Blinded readings of morphometry
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unblinded readings of X-rays
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unblinded readings of morphometry
Number of subjects: 50
Study: 1888619

Group type: EXPERIMENTAL
Intervention: Individualised drug information wallet (leaflet group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual verbal counselling (control group)
Number of subjects: 125
Study: 31965675

Group type: EXPERIMENTAL
Intervention: MOtiVational intErviewing InTervention (MOVE IT)
Number of subjects: 26
Study: 30196448

Group type: EXPERIMENTAL
Intervention: 0.3 g kg‐1 BM NaHCO3 (SBC3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2 g kg‐1 BM NaHCO3 (SBC2)
Number of subjects: 10